Home

Mischung krank Verkäufer met inhibitor Wrack seltsam Tinte

Molecules | Free Full-Text | Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors
Molecules | Free Full-Text | Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors

Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor
Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor

Frontiers | Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
Frontiers | Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine

Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect

Recent advances in the discovery of small molecule c-Met Kinase inhibitors - ScienceDirect
Recent advances in the discovery of small molecule c-Met Kinase inhibitors - ScienceDirect

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer | Science Translational Medicine
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer | Science Translational Medicine

PDF] Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer | Semantic Scholar
PDF] Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer | Semantic Scholar

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters

Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink

c-Met inhibitor - Wikipedia
c-Met inhibitor - Wikipedia

Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research

Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer

Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition | SpringerLink
Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition | SpringerLink

HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram
HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters

JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review

PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar

Pathway activation mapping of c-MET inhibitor effects in high-and... | Download Scientific Diagram
Pathway activation mapping of c-MET inhibitor effects in high-and... | Download Scientific Diagram

Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met | Scientific Reports
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met | Scientific Reports

c-Met inhibitor 1 | c-Met/HGFR Inhibitor | MedChemExpress
c-Met inhibitor 1 | c-Met/HGFR Inhibitor | MedChemExpress